Cardiol Therapeutics Inc. (TSE:CRDL) Director Acquires C$75,072.00 in Stock

Cardiol Therapeutics Inc. (TSE:CRDL) Director David Elsley acquired 40,000 shares of the stock in a transaction dated Monday, December 16th. The shares were bought at an average price of C$1.88 per share, with a total value of C$75,072.00.

Cardiol Therapeutics Stock Performance

Shares of CRDL stock opened at C$1.89 on Friday. The company has a debt-to-equity ratio of 1.07, a current ratio of 2.39 and a quick ratio of 6.84. Cardiol Therapeutics Inc. has a one year low of C$1.07 and a one year high of C$4.26. The business’s 50 day simple moving average is C$2.39 and its 200 day simple moving average is C$2.71. The stock has a market capitalization of C$132.07 million, a PE ratio of -4.30 and a beta of 0.70.

About Cardiol Therapeutics

Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.